Antipsychotic trials in schizophrenia: the CATIE project
Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectivenes...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Cambridge
Cambridge University Press
2010
|
| Schlagworte: | |
| Online-Zugang: | BSB01 FHN01 Volltext |
| Zusammenfassung: | Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading |
| Beschreibung: | Title from publisher's bibliographic system (viewed on 05 Oct 2015) |
| Beschreibung: | 1 online resource (xvii, 312 pages) |
| ISBN: | 9780511712265 |
| DOI: | 10.1017/CBO9780511712265 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043944697 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 161206s2010 |||| o||u| ||||||eng d | ||
| 020 | |a 9780511712265 |c Online |9 978-0-511-71226-5 | ||
| 024 | 7 | |a 10.1017/CBO9780511712265 |2 doi | |
| 035 | |a (ZDB-20-CBO)CR9780511712265 | ||
| 035 | |a (OCoLC)992888749 | ||
| 035 | |a (DE-599)BVBBV043944697 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 |a DE-92 | ||
| 082 | 0 | |a 616.89/8061 |2 22 | |
| 084 | |a YH 6115 |0 (DE-625)153561:12921 |2 rvk | ||
| 245 | 1 | 0 | |a Antipsychotic trials in schizophrenia |b the CATIE project |c edited by T. Scott Stroup, Jeffrey A. Lieberman |
| 264 | 1 | |a Cambridge |b Cambridge University Press |c 2010 | |
| 300 | |a 1 online resource (xvii, 312 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Title from publisher's bibliographic system (viewed on 05 Oct 2015) | ||
| 505 | 8 | |a Machine generated contents note: Introduction: Rationale for an independent, pragmatic study of antipsychotic treatments Jeffrey Lieberman; 1. Study design and protocol development process Scott Stroup, Joe McEvoy and Jeffrey Lieberman; 2. Statistical considerations Sonia Davis and Gary Koch; 3. Efficacy and effectiveness Joe McEvoy, Scott Stroup and Jeffrey Lieberman; 4. Measures of global effectiveness, cost-effectiveness Bob Rosenheck; 5. Quality of life and recovery Marvin Swartz; 6. Neurocognition Rich Keefe; 7. Vocational outcomes Sandra Resnick et al.; 8. Family outcomes Deborah Perlick et al.; 9. Neurologic side effects Stan Caroff, Del Miller and Bob Rosenheck; 10. Metabolic side effects and risk of cardiovascular disease Jonathan Meyer, Don Goff and Joe McEvoy; 11. Substance abuse Fred Reimherr and Marvin Swartz; 12. Violence Jeff Swanson and Richard van Dorn; 13. Genetics Patrick Sullivan; 14. Human subjects considerations Scott Stroup, Scott Kim and Paul Appelbaum; 15. Pharmacokinetics Bruce Pollock; 16. Implications of the CATIE project on research design and implementation Scott Stroup and Jeffrey Lieberman; 17. Conclusions-impact of the study and implications for dissemination, practice and policy formation Scott Stroup, Bob Rosenheck and Jeffrey Lieberman; Index | |
| 520 | |a Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading | ||
| 610 | 2 | 4 | |a CATIE Project |
| 650 | 4 | |a Antipsychotic drugs / Testing | |
| 650 | 4 | |a Schizophrenia / Chemotherapy | |
| 650 | 0 | 7 | |a Psychopharmakotherapie |0 (DE-588)4236424-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Schizophrenie |0 (DE-588)4052527-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Klinisches Experiment |0 (DE-588)4164223-5 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Schizophrenie |0 (DE-588)4052527-2 |D s |
| 689 | 0 | 1 | |a Psychopharmakotherapie |0 (DE-588)4236424-3 |D s |
| 689 | 0 | 2 | |a Klinisches Experiment |0 (DE-588)4164223-5 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a Stroup, T. Scott |d 1960- |4 edt | |
| 700 | 1 | |a Lieberman, Jeffrey A. |d 1948- |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druckausgabe |z 978-0-521-89533-0 |
| 856 | 4 | 0 | |u https://doi.org/10.1017/CBO9780511712265 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-20-CBO | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029353668 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1017/CBO9780511712265 |l BSB01 |p ZDB-20-CBO |q BSB_PDA_CBO |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1017/CBO9780511712265 |l FHN01 |p ZDB-20-CBO |q FHN_PDA_CBO |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804176889904889856 |
|---|---|
| any_adam_object | |
| author2 | Stroup, T. Scott 1960- Lieberman, Jeffrey A. 1948- |
| author2_role | edt edt |
| author2_variant | t s s ts tss j a l ja jal |
| author_facet | Stroup, T. Scott 1960- Lieberman, Jeffrey A. 1948- |
| building | Verbundindex |
| bvnumber | BV043944697 |
| classification_rvk | YH 6115 |
| collection | ZDB-20-CBO |
| contents | Machine generated contents note: Introduction: Rationale for an independent, pragmatic study of antipsychotic treatments Jeffrey Lieberman; 1. Study design and protocol development process Scott Stroup, Joe McEvoy and Jeffrey Lieberman; 2. Statistical considerations Sonia Davis and Gary Koch; 3. Efficacy and effectiveness Joe McEvoy, Scott Stroup and Jeffrey Lieberman; 4. Measures of global effectiveness, cost-effectiveness Bob Rosenheck; 5. Quality of life and recovery Marvin Swartz; 6. Neurocognition Rich Keefe; 7. Vocational outcomes Sandra Resnick et al.; 8. Family outcomes Deborah Perlick et al.; 9. Neurologic side effects Stan Caroff, Del Miller and Bob Rosenheck; 10. Metabolic side effects and risk of cardiovascular disease Jonathan Meyer, Don Goff and Joe McEvoy; 11. Substance abuse Fred Reimherr and Marvin Swartz; 12. Violence Jeff Swanson and Richard van Dorn; 13. Genetics Patrick Sullivan; 14. Human subjects considerations Scott Stroup, Scott Kim and Paul Appelbaum; 15. Pharmacokinetics Bruce Pollock; 16. Implications of the CATIE project on research design and implementation Scott Stroup and Jeffrey Lieberman; 17. Conclusions-impact of the study and implications for dissemination, practice and policy formation Scott Stroup, Bob Rosenheck and Jeffrey Lieberman; Index |
| ctrlnum | (ZDB-20-CBO)CR9780511712265 (OCoLC)992888749 (DE-599)BVBBV043944697 |
| dewey-full | 616.89/8061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.89/8061 |
| dewey-search | 616.89/8061 |
| dewey-sort | 3616.89 48061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1017/CBO9780511712265 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04529nmm a2200541zc 4500</leader><controlfield tag="001">BV043944697</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">161206s2010 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780511712265</subfield><subfield code="c">Online</subfield><subfield code="9">978-0-511-71226-5</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1017/CBO9780511712265</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-20-CBO)CR9780511712265</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)992888749</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043944697</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-92</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.89/8061</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YH 6115</subfield><subfield code="0">(DE-625)153561:12921</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antipsychotic trials in schizophrenia</subfield><subfield code="b">the CATIE project</subfield><subfield code="c">edited by T. Scott Stroup, Jeffrey A. Lieberman</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge</subfield><subfield code="b">Cambridge University Press</subfield><subfield code="c">2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xvii, 312 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Title from publisher's bibliographic system (viewed on 05 Oct 2015)</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Machine generated contents note: Introduction: Rationale for an independent, pragmatic study of antipsychotic treatments Jeffrey Lieberman; 1. Study design and protocol development process Scott Stroup, Joe McEvoy and Jeffrey Lieberman; 2. Statistical considerations Sonia Davis and Gary Koch; 3. Efficacy and effectiveness Joe McEvoy, Scott Stroup and Jeffrey Lieberman; 4. Measures of global effectiveness, cost-effectiveness Bob Rosenheck; 5. Quality of life and recovery Marvin Swartz; 6. Neurocognition Rich Keefe; 7. Vocational outcomes Sandra Resnick et al.; 8. Family outcomes Deborah Perlick et al.; 9. Neurologic side effects Stan Caroff, Del Miller and Bob Rosenheck; 10. Metabolic side effects and risk of cardiovascular disease Jonathan Meyer, Don Goff and Joe McEvoy; 11. Substance abuse Fred Reimherr and Marvin Swartz; 12. Violence Jeff Swanson and Richard van Dorn; 13. Genetics Patrick Sullivan; 14. Human subjects considerations Scott Stroup, Scott Kim and Paul Appelbaum; 15. Pharmacokinetics Bruce Pollock; 16. Implications of the CATIE project on research design and implementation Scott Stroup and Jeffrey Lieberman; 17. Conclusions-impact of the study and implications for dissemination, practice and policy formation Scott Stroup, Bob Rosenheck and Jeffrey Lieberman; Index</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">CATIE Project</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antipsychotic drugs / Testing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Schizophrenia / Chemotherapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Psychopharmakotherapie</subfield><subfield code="0">(DE-588)4236424-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Schizophrenie</subfield><subfield code="0">(DE-588)4052527-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Klinisches Experiment</subfield><subfield code="0">(DE-588)4164223-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Schizophrenie</subfield><subfield code="0">(DE-588)4052527-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Psychopharmakotherapie</subfield><subfield code="0">(DE-588)4236424-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Klinisches Experiment</subfield><subfield code="0">(DE-588)4164223-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stroup, T. Scott</subfield><subfield code="d">1960-</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lieberman, Jeffrey A.</subfield><subfield code="d">1948-</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druckausgabe</subfield><subfield code="z">978-0-521-89533-0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1017/CBO9780511712265</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-20-CBO</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029353668</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1017/CBO9780511712265</subfield><subfield code="l">BSB01</subfield><subfield code="p">ZDB-20-CBO</subfield><subfield code="q">BSB_PDA_CBO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1017/CBO9780511712265</subfield><subfield code="l">FHN01</subfield><subfield code="p">ZDB-20-CBO</subfield><subfield code="q">FHN_PDA_CBO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043944697 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:39:22Z |
| institution | BVB |
| isbn | 9780511712265 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029353668 |
| oclc_num | 992888749 |
| open_access_boolean | |
| owner | DE-12 DE-92 |
| owner_facet | DE-12 DE-92 |
| physical | 1 online resource (xvii, 312 pages) |
| psigel | ZDB-20-CBO ZDB-20-CBO BSB_PDA_CBO ZDB-20-CBO FHN_PDA_CBO |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Cambridge University Press |
| record_format | marc |
| spelling | Antipsychotic trials in schizophrenia the CATIE project edited by T. Scott Stroup, Jeffrey A. Lieberman Cambridge Cambridge University Press 2010 1 online resource (xvii, 312 pages) txt rdacontent c rdamedia cr rdacarrier Title from publisher's bibliographic system (viewed on 05 Oct 2015) Machine generated contents note: Introduction: Rationale for an independent, pragmatic study of antipsychotic treatments Jeffrey Lieberman; 1. Study design and protocol development process Scott Stroup, Joe McEvoy and Jeffrey Lieberman; 2. Statistical considerations Sonia Davis and Gary Koch; 3. Efficacy and effectiveness Joe McEvoy, Scott Stroup and Jeffrey Lieberman; 4. Measures of global effectiveness, cost-effectiveness Bob Rosenheck; 5. Quality of life and recovery Marvin Swartz; 6. Neurocognition Rich Keefe; 7. Vocational outcomes Sandra Resnick et al.; 8. Family outcomes Deborah Perlick et al.; 9. Neurologic side effects Stan Caroff, Del Miller and Bob Rosenheck; 10. Metabolic side effects and risk of cardiovascular disease Jonathan Meyer, Don Goff and Joe McEvoy; 11. Substance abuse Fred Reimherr and Marvin Swartz; 12. Violence Jeff Swanson and Richard van Dorn; 13. Genetics Patrick Sullivan; 14. Human subjects considerations Scott Stroup, Scott Kim and Paul Appelbaum; 15. Pharmacokinetics Bruce Pollock; 16. Implications of the CATIE project on research design and implementation Scott Stroup and Jeffrey Lieberman; 17. Conclusions-impact of the study and implications for dissemination, practice and policy formation Scott Stroup, Bob Rosenheck and Jeffrey Lieberman; Index Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading CATIE Project Antipsychotic drugs / Testing Schizophrenia / Chemotherapy Psychopharmakotherapie (DE-588)4236424-3 gnd rswk-swf Schizophrenie (DE-588)4052527-2 gnd rswk-swf Klinisches Experiment (DE-588)4164223-5 gnd rswk-swf Schizophrenie (DE-588)4052527-2 s Psychopharmakotherapie (DE-588)4236424-3 s Klinisches Experiment (DE-588)4164223-5 s 1\p DE-604 Stroup, T. Scott 1960- edt Lieberman, Jeffrey A. 1948- edt Erscheint auch als Druckausgabe 978-0-521-89533-0 https://doi.org/10.1017/CBO9780511712265 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Antipsychotic trials in schizophrenia the CATIE project Machine generated contents note: Introduction: Rationale for an independent, pragmatic study of antipsychotic treatments Jeffrey Lieberman; 1. Study design and protocol development process Scott Stroup, Joe McEvoy and Jeffrey Lieberman; 2. Statistical considerations Sonia Davis and Gary Koch; 3. Efficacy and effectiveness Joe McEvoy, Scott Stroup and Jeffrey Lieberman; 4. Measures of global effectiveness, cost-effectiveness Bob Rosenheck; 5. Quality of life and recovery Marvin Swartz; 6. Neurocognition Rich Keefe; 7. Vocational outcomes Sandra Resnick et al.; 8. Family outcomes Deborah Perlick et al.; 9. Neurologic side effects Stan Caroff, Del Miller and Bob Rosenheck; 10. Metabolic side effects and risk of cardiovascular disease Jonathan Meyer, Don Goff and Joe McEvoy; 11. Substance abuse Fred Reimherr and Marvin Swartz; 12. Violence Jeff Swanson and Richard van Dorn; 13. Genetics Patrick Sullivan; 14. Human subjects considerations Scott Stroup, Scott Kim and Paul Appelbaum; 15. Pharmacokinetics Bruce Pollock; 16. Implications of the CATIE project on research design and implementation Scott Stroup and Jeffrey Lieberman; 17. Conclusions-impact of the study and implications for dissemination, practice and policy formation Scott Stroup, Bob Rosenheck and Jeffrey Lieberman; Index CATIE Project Antipsychotic drugs / Testing Schizophrenia / Chemotherapy Psychopharmakotherapie (DE-588)4236424-3 gnd Schizophrenie (DE-588)4052527-2 gnd Klinisches Experiment (DE-588)4164223-5 gnd |
| subject_GND | (DE-588)4236424-3 (DE-588)4052527-2 (DE-588)4164223-5 |
| title | Antipsychotic trials in schizophrenia the CATIE project |
| title_auth | Antipsychotic trials in schizophrenia the CATIE project |
| title_exact_search | Antipsychotic trials in schizophrenia the CATIE project |
| title_full | Antipsychotic trials in schizophrenia the CATIE project edited by T. Scott Stroup, Jeffrey A. Lieberman |
| title_fullStr | Antipsychotic trials in schizophrenia the CATIE project edited by T. Scott Stroup, Jeffrey A. Lieberman |
| title_full_unstemmed | Antipsychotic trials in schizophrenia the CATIE project edited by T. Scott Stroup, Jeffrey A. Lieberman |
| title_short | Antipsychotic trials in schizophrenia |
| title_sort | antipsychotic trials in schizophrenia the catie project |
| title_sub | the CATIE project |
| topic | CATIE Project Antipsychotic drugs / Testing Schizophrenia / Chemotherapy Psychopharmakotherapie (DE-588)4236424-3 gnd Schizophrenie (DE-588)4052527-2 gnd Klinisches Experiment (DE-588)4164223-5 gnd |
| topic_facet | CATIE Project Antipsychotic drugs / Testing Schizophrenia / Chemotherapy Psychopharmakotherapie Schizophrenie Klinisches Experiment |
| url | https://doi.org/10.1017/CBO9780511712265 |
| work_keys_str_mv | AT strouptscott antipsychotictrialsinschizophreniathecatieproject AT liebermanjeffreya antipsychotictrialsinschizophreniathecatieproject |